We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Why GlaxoSmithKline plc, BT Group plc And Travis Perkins plc Offer Unmissable Value For Money!

Royston Wild explains why GlaxoSmithKline plc (LON: GSK), BT Group plc (LON: BT) and Travis Perkins plc (LON: TPK) all offer stonking bang for your buck.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Today I am looking at three of the hottest blue-chip bargains that London has to offer.

GlaxoSmithKline

I am convinced that medicines monster GlaxoSmithKline (LSE: GSK) provides brilliant growth and income prospects at an attractive price. The company has pulled out all the stops to kick-start its product pipeline and replace its ailing line of patent-related casualties like Advair, and GlaxoSmithKline currently has 40 new molecular entities (or NMEs) in late-stage testing.

Should you buy Bt Group Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

The fruits of this hard work promise to deliver jumbo revenue growth in the years ahead, in my opinion, as a combination of rising populations and massive healthcare investment in emerging regions blasts global sales higher. As a result GlaxoSmithKline is anticipated to recover from a 21% earnings slippage this year to post a 12% rise in 2016, driving a P/E multiple of 17.2 times for 2015 to a very decent 15.5 times.

On top of this, GlaxoSmithKline’s vow to shell out a dividend of 80p per share through to the close of 2017 yields an impressive 6%, making mincemeat of the FTSE 100 average of 3.5%. With the business’ earnings outlook steadily improving, and the firm juggling its asset portfolio with the likes of Novartis to further boost the cash pile, I fully expect GlaxoSmithKline to meet these targets.

BT Group

The ‘quad-play’ entertainment sector has been one of the hottest plays in town in recent years — from Sky buying out its Italian and German arms, to Vodafone making its foray into the segment through the purchase of Kabel Deutschland and Spain’s Ono, companies the world over are betting big on this hot growth sector. With this in mind I believe BT Group (LSE: BT-A) is a great selection for clever investors.

BT has taken a shrewd approach to battling Sky by dismantling its stranglehold on British sports broadcasting, while the imminent launch of drama channel AMC Networks provides a credible alternative to its rival’s Sky Atlantic offering. With its fibre-laying drive also boosting broadband interest, the City expects BT to recover from a 3% earnings dip in the 12 months to March 2016 with a 7% recovery the following year.

Such figures result in ultra-low P/E ratios of 13.6 times and 12.8 times correspondingly, and the telecoms play’s bright profits outlook is predicted to keep dividends rising at breakneck speed, too. Last year’s reward of 12.4p per share is anticipated to rise to 14p in 2016 and 15.6p the following year, creating chunky yields of 3.3% and 3.7%.

Travis Perkins

Thanks to the buoyant construction market, I believe Travis Perkins (LSE: TPK) is a solid selection for those seeking great growth prospects. Indeed, a supportive industry backcloth has prompted the business to add a further 400 stores to its already-sprawling network in the next few years, thanks in no small part to resplendent activity across the housing sector.

And with the UK economy clicking steadily through the gears, I expect the top-line at Travis Perkins to keep on rocking. This view is shared by the City, and the retailer is expected to enjoy earnings growth of 9% in 2015 and 14% next year. As a result the stock sports terrific P/E multiples of 15.3 times and 13.4 times for 2015 and 2016 correspondingly.

In the medium term Travis Perkins is expected to lag the wider market in the dividend stakes, however — predicted payouts of 45.8p per share for 2015 and 54.4p for 2016 create handy, if unspectacular, yields of 2.3% and 2.7% respectively. But like BT, I believe investors should pay attention to the excellent growth rate in Travis Perkins’ annual dividend, a phenomenon that I expect to continue as earnings rocket higher.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Content white businesswoman being congratulated by colleagues at her retirement party
Investing Articles

How investing in a Cash ISA could cost you a comfortable retirement

Cash ISAs are celebrated for the brilliant tax benefits they provide. But could focusing on them cost savers the chance…

Read more »

Young black woman in a wheelchair working online from home
Investing Articles

How much could Barclays shares pay in dividends by 2028?

Barclays is one of the FTSE 100's most popular dividend shares. How much could they provide over the next three…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

With a 6% yield and a P/E of just 7.4, is this share a screaming buy for a second income?

Mark Hartley looks at the second income potential of a popular UK dividend stock that still looks undervalued despite compelling…

Read more »

Investing Articles

Forget Nvidia! This ETF is booming inside my Stocks and Shares ISA

A thematic ETF inside this writer's ISA has more doubled the return of Nvidia stock so far in 2026. But…

Read more »

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing Articles

These cheap FTSE 250 shares could deliver a £1,550 ISA income in just 12 months!

Searching for the best low-cost dividend stocks to buy? Royston Wild reveals two FTSE 250 property shares with yields above…

Read more »

Landlady greets regular at real ale pub
Investing Articles

How much in dividends will these high-yield shares generate in 2026?

With 9.5% and 8.4% dividend yields, what makes these FTSE 100 and FTSE 250 high-yield heroes so special? Royston Wild…

Read more »

British pound data
Investing Articles

£5,000 invested in Nvidia shares when ChatGPT was released is now worth…

The rise of Nvidia shares was kickstarted by the advent of ChatGPT. Our author takes a look at how much…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

Did HSBC just become the FTSE 100’s best dividend stock?

HSBC has long been a strong dividend stock, but could it now be one of the best on the entire…

Read more »